New and Investigational Agents for Irritable Bowel Syndrome

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3–4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.

Original languageEnglish (US)
Article number46
JournalCurrent Gastroenterology Reports
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Irritable Bowel Syndrome
Gastrointestinal Diseases
Investigational Drugs
Constipation
Bile Acids and Salts
Health Care Costs
Diarrhea
Therapeutics
Morbidity
Pain
Pharmaceutical Preparations
Population

Keywords

  • Constipation
  • Diarrhea
  • Drugs
  • Functional gastrointestinal disorders
  • Pain
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

New and Investigational Agents for Irritable Bowel Syndrome. / Wadhwa, Akhilesh; Camilleri, Michael; Grover, Madhusudan.

In: Current Gastroenterology Reports, Vol. 17, No. 12, 46, 01.12.2015.

Research output: Contribution to journalArticle

@article{9179b0f8702745f8baec37188898cc09,
title = "New and Investigational Agents for Irritable Bowel Syndrome",
abstract = "Irritable bowel syndrome (IBS) affects about 15 {\%} of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3–4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.",
keywords = "Constipation, Diarrhea, Drugs, Functional gastrointestinal disorders, Pain, Treatment",
author = "Akhilesh Wadhwa and Michael Camilleri and Madhusudan Grover",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11894-015-0473-x",
language = "English (US)",
volume = "17",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - New and Investigational Agents for Irritable Bowel Syndrome

AU - Wadhwa, Akhilesh

AU - Camilleri, Michael

AU - Grover, Madhusudan

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3–4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.

AB - Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3–4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.

KW - Constipation

KW - Diarrhea

KW - Drugs

KW - Functional gastrointestinal disorders

KW - Pain

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84943626717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943626717&partnerID=8YFLogxK

U2 - 10.1007/s11894-015-0473-x

DO - 10.1007/s11894-015-0473-x

M3 - Article

C2 - 26446557

AN - SCOPUS:84943626717

VL - 17

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 12

M1 - 46

ER -